Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders-Reference-Cited by-全球学者库

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders

Published:2023-08-11 Issue:8 Volume:16 Page:1140
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Hang Abraham¹,Feldman Samuel¹,Amin Aana P.²,Ochoa Jorge A. Rivas²,Park Susanna S.¹^ORCID

Affiliation:

1. Department of Ophthalmology & Vision Science, Ernest E. Tschannen Eye Institute, University of California Davis Eye Center, 4860 Y Street, Sacramento, CA 95817, USA

2. School of Medicine, University of California Davis, Sacramento, CA 95817, USA

Abstract

Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal neovascularization as well as retinal vascular leakage leading to macular edema. As such, VEGF plays an important role in mediating visually significant complications associated with common retinal disorders such as diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. Various drugs that inhibit vascular endothelial growth factors (anti-VEGF therapies) have been developed to minimize vision loss associated with these disorders. These drugs are injected into the vitreous cavity in a clinic setting at regular intervals. This article provides an overview of the various anti-VEGF drugs used in ophthalmology and the common retinal conditions that benefit from this therapy.

Funder

Barbara A. & Alan M. Roth, MD Endowed Chair for Discovery, Education and Patient Care in Vision Science from the University of California Davis

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/8/1140/pdf

Reference142 articles.

1. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber;Ide;Am. J. Roentgenol.,1939

2. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials—An interview with Napoleone Ferrara by Domenico Ribatti;Ferrara;Int. J. Dev. Biol.,2011

3. Vascular endothelial growth factor (VEGF)—Key factor in normal and pathological angiogenesis;Melincovici;Rom. J. Morphol. Embryol.,2018

4. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies;Shibuya;Genes Cancer,2011

5. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis;Yonekura;J. Biol. Chem.,1999

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy—A Review;Diagnostics;2023-12-22

2. Release of Pro-Inflammatory/Angiogenic Factors by Retinal Microvascular Cells Is Mediated by Extracellular Vesicles Derived from M1-Activated Microglia;International Journal of Molecular Sciences;2023-12-19